Navigation Links
National Jewish Health researchers discover how virulent bacteria
Date:2/1/2010

Researchers at National Jewish Health have discovered how the virulent food-borne bacteria Listeria monocytogenes induces infected immune cells to sabotage their own defensive response. The studies offer insight into host-pathogen interactions and suggest potential therapeutic targets for food poisoning, tuberculosis and autoimmune diseases.

In the Feb. 15 issue of the Journal of Experimental Medicine, Laurel Lenz, PhD, and his colleagues report that macrophages infected by the bacteria Listeria release interferon-αβ (IFN- αβ), which makes them and nearby immune cells unresponsive to activation signals. This reduces immune resistance to the bacteria, which causes thousands of cases of food poisoning -- and more than 500 deaths -- each year in the United States.

"Listeria appears to benefit by triggering an endogenous pathway of the host that dampens its own immune response," said Dr. Lenz. "Our findings suggest that Listeria increases its survival in infected individuals by inducing cross-talk between host interferon signaling pathways."

When patrolling immune-system cells encounter non-pathogenic microbes, they normally engulf and destroy them. However, certain pathogens such as Listeria can grow within immune cells, which then release alarm signals to other nearby cells. One of these alarms is IFN-αβ. IFN-αβ protects host cells from viral infection. However, IFN- also increases growth of Listeria and certain other bacteria.

Dr. Lenz and his colleagues showed that IFN-αβ does this by down-regulating expression of receptors for interferon-γ (IFN-γ). With its receptors down-regulated, IFN-γ cannot drive resting macrophages into an activated state that is especially effective against bacterial pathogens inside the cell.

"IFN-αβ acts as a sort of anesthetic to numb the response of immune cells to IFN-γ," said Dr. Lenz.

The research highlights the crosstalk that exists between the antibacterial and anti-viral arms of the immune response. Dr. Lenz's findings demonstrate that IFN-αβ, well known to stimulate antiviral defenses, dampens anti-bacterial activity as well.

He speculates that this may be a way for the immune system to more efficiently defend against viral pathogens, while avoiding collateral damage caused by an overactive immune cells. In fact, interferon-β, a medication widely used for multiple sclerosis, may do just that. Dr. Lenz speculates that this medication may act in part by down-regulating expression of IFN- γ receptors on myeloid cells, thus reducing the stimulation of autoimmune T cells.

The next step will be to define more precisely how IFN-αβ mediates down-regulation of the IFN-γ receptors, and to determine whether prevention of these effects improves resistance to infection by Listeria and other bacterial pathogens.


'/>"/>

Contact: Adam Dormuth
dormutha@njhealth.org
303-398-1082
National Jewish Medical and Research Center
Source:Eurekalert

Related biology news :

1. Wolves find happy hunting grounds in Yellowstone National Park
2. BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo
3. ESMO International Symposium on Immunology
4. Story tips from the US Department of Energys Oak Ridge National Laboratory, September 2007
5. Office of the Director of National Intelligence, CIO to Speak at Government Security Conference
6. Director of National Intelligence to Speak at Conference
7. Singapore National Science and Technology Awards
8. Conservation International and Toyota partner to protect Philippines rain forests
9. International team shows mercury concentrations in fish respond quickly to increased deposition
10. International team shows mercury concentrations in fish respond quickly to increased deposition
11. Office of the Director of National Intelligence, CIO to Speak at Government Security Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology: